No Data
No Data
Apogee Therapeutics Starts Phase 2 Trial for Atopic Dermatitis Drug
Express News | Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of Apg777, a Novel Subcutaneous Half-Life Extended Anti-Il-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Buy Rating on Apogee Therapeutics: Promising Drug Developments and Strong Financials
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics' Q1 Net Loss Widens
Apogee Therapeutics (APGE) reported a Q1 net loss Monday of $32.1 million, widening from its $12.5 million net loss a year earlier. Analysts polled by Capital IQ expected a net loss of $28.9 million.
Apogee Therapeutics | 10-Q: Quarterly report
No Data